Recently, the 12th China Listed Company Summit Forum, organized by National Business Daily, was successfully held.

This year’s forum focused on the theme “Energize Capital Markets, Boost Investor Confidence,” and explored the current challenges and opportunities in China’s capital markets, while also seeking strategies for long-term, healthy development.

Now in its 12th year, the forum has attracted over 1,200 participating companies and invited more than 700 guest speakers. It has drawn a combined online and offline audience of over 3.5 million people, making it one of the most influential events in China’s capital markets.

During the forum, after nearly three months of intense evaluation and rigorous selection, the results of the 13th China Listed Company Reputation Ranking were officially unveiled. Imeik was honored as the “Most Promising Listed Company in the Big Health Sector”, thanks to its solid performance and strong growth prospects.

Notably, this is the second consecutive year that Imeik has been featured on the China Listed Company Reputation Ranking. This achievement affirms the company’s economic contributions and brand value, while also reflecting its influence and leadership in shaping the future of the industry.

In recent years, Imeik has continuously enhanced its innovation capacity, expanded its product pipeline, and increased its market share. From 2018 to 2022, the company achieved a compound annual growth rate (CAGR) of 56.7% in revenue and 81.7% in net profit, demonstrating its strong resilience and growth momentum.

Today, China has become the world’s third-largest medical aesthetics market. The vast market potential and industry tailwinds are expected to drive significant opportunities for growth. As a leader at the forefront of China’s medical aesthetics sector, Imeik is now setting its sights on a broader global stage—aspiring to match world-class standards and create enduring value for the industry and society.